** Piper Sandler upgrades shares of eyecare technology co Sight Sciences SGHT.O to "overweight" from "neutral", citing bullish stance on co's TearCare opportunity and improvement in its surgical glaucoma business in FY26

** Says its surgical glaucoma business that has performed better than expected in 2025, has "brighter days ahead in FY ’26"

** Raises PT to $9 from $5, representing over 20% upside to stock's last close

** Sight Sciences shares rise about 5.2% to $7.87 premarket in low trading volumes

** Piper says, despite strong long-term potential for TearCare, investors should be cautious in near term as the company aims to achieve insurance reimbursement

** 3 of 7 brokerages rate SGHT "buy" or higher, and rest rate "hold"; their median PT is $8.55 - data compiled by LSEG

** In the last 12 months, stock fell 5.7%

(Reporting by Kanchana Chakravarty in Bengaluru)

((Kanchana.Chakravarty@thomsonreuters.com;))